Venus gets market authorisation from Swiss drug authority

Tags: Companies
Pharma major Venus Remedies has secured its first marketing authorisation in Switzerland from Swiss drug authority 'Swissmedic' for its oncology drug 'Gemcitabine'.

The marketing approval for Gemcitabine will help the company further strengthen its oncology portfolio and improve its presence in this space, Venus Remedies said in a statement here today.

The Panchkula-based company plans to launch the drug early next quarter and the product will be launched in Switzerland by Swiss Pharma GmbH, with which Venus has a marketing tie-up, it said.

"The launch of this product will add to the company's top line and bottom line in the coming quarters," it said.

Venus Remedies has already received more than 20 marketing approvals for Gemcitabine injection from various countries. The product is being sold in the UK, Poland and Germany.

Gemcitabine is an anti-cancer drug used for the treatment of a variety of cancerous conditions, including the cancer of the lungs, pancreas, bladder and breast.

Post new comment

E-mail ID will not be published
CAPTCHA
This question is for testing whether you are a human visitor and to prevent automated spam submissions.

EDITORIAL OF THE DAY

  • Bureaucrats have enjoyed flying miles at taxpayer expense for too long

    The beleaguered Indian taxpayer will certainly applaud prime minister Narendra Modi’s attempt to deliver on his promise of cutting down fiscal defic

FC NEWSLETTER

Stay informed on our latest news!

INTERVIEWS

GV Nageswara Rao

MD & CEO, IDBI Federal Life

Timothy Moe

Goldman Sachs

Chander Mohan Sethi

CMD, Reckitt Benckiser India

COLUMNIST

Varun Dutt

<b>Riskfactor</b>: CHAIN REACTION

A domino effect is the cumulative effect produced when one ...

Zehra Naqvi

Rememberance and forgetting are crucial

Memories are so vital to our lives that they can ...

Dharmendra Khandal

Sandalwood may get extinct if not protected

When we talk of sandalwood, the most common usage that ...

INTERVIEWS

William D. Green

Chairman & CEO, Accenture